Related Experiment Video
Updated: Aug 9, 2026
11:02
Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
Lethal midline granuloma-nasal natural killer/T-cell lymphoma
William M Mendenhall1, Kenneth R Olivier, James W Lynch
1Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA. mendewil@shands.ufl.edu
American Journal of Clinical Oncology
|April 8, 2006
Summary
Lethal midline granuloma-nasal natural killer (NK) T-cell lymphoma (LMG-NTL) is a rare, aggressive nasal lymphoma. Treatment strategies require further investigation due to poor prognosis and frequent local-regional failure.
Area of Science:
- Oncology
- Hematology
- Pathology
Background:
- Lethal midline granuloma (LMG) is a destructive idiopathic midline lesion.
- Nasal natural killer (NK) T-cell lymphoma (LMG-NTL) is a rare subtype of extranodal NK/T-cell lymphoma.
- Distinguishing LMG-NTL from other nasal conditions is clinically challenging.
Purpose of the Study:
- To discuss lethal midline granuloma (LMG) and its association with nasal natural killer (NK) T-cell lymphoma (LMG-NTL).
- To review the characteristics, treatment, and prognosis of LMG-NTL.
Main Methods:
- Comprehensive literature review of LMG and LMG-NTL.
Main Results:
- LMG-NTL predominantly affects males, originates in the nasal cavity, and presents across a wide age spectrum.
- The 5-year survival rate for LMG-NTL is approximately 20%, significantly lower than other head and neck lymphomas.
- Treatment failure typically occurs early, with local-regional disease progression being the primary pattern.
Conclusions:
- LMG-NTL is a rare nasal NK/T-cell lymphoma with an aggressive clinical course.
- Effective chemotherapy and more aggressive local-regional treatment are suggested by patterns of failure.
- Early and accurate diagnosis is crucial for managing this challenging entity.
